Form 4: Arcus Biosciences COO Sells Shares to Cover Tax Obligations

Arcus Biosciences' Chief Operating Officer, Jennifer Jarrett, sold 27,501 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Summary

• Jennifer Jarrett, the Chief Operating Officer of Arcus Biosciences, sold 27,501 shares of common stock on December 15, 2024.
• The sale was executed at a price of $16.08 per share.
• This transaction was a 'net settlement' by the company to cover tax withholding obligations associated with the vesting of her restricted stock units (RSUs).
• Following the transaction, Ms. Jarrett directly owns 163,369 shares of Arcus Biosciences common stock.

Sentiment

Score: 5

Explanation: This is a neutral event, a routine transaction for tax purposes, and does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when RSUs vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the biotechnology industry.
• Many companies use RSUs as part of their compensation packages, leading to similar transactions by executives at other firms such as Gilead Sciences, Regeneron, and Vertex Pharmaceuticals.
• The number of shares sold and the price are specific to the individual's holdings and the company's stock price at the time of vesting.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Arcus Biosciences, Jennifer Jarrett, Chief Operating Officer, stock sale, Form 4, insider trading, restricted stock units, tax obligations, net settlement